Wall Street brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to report earnings of ($0.55) per share for the current quarter, according to Zacks. Four analysts have made estimates for Assembly Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at $0.17. Assembly Biosciences reported earnings per share of ($0.72) in the same quarter last year, which would suggest a positive year over year growth rate of 23.6%. The firm is expected to issue its next quarterly earnings results on Monday, August 3rd.
On average, analysts expect that Assembly Biosciences will report full year earnings of ($3.13) per share for the current fiscal year, with EPS estimates ranging from ($3.58) to ($2.32). For the next financial year, analysts expect that the company will post earnings of ($4.03) per share, with EPS estimates ranging from ($5.76) to ($3.22). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.22. Assembly Biosciences had a negative return on equity of 45.43% and a negative net margin of 601.75%. The business had revenue of $4.08 million for the quarter, compared to the consensus estimate of $3.82 million.
In related news, EVP Richard James Colonno sold 7,812 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $15.04, for a total transaction of $117,492.48. Following the completion of the transaction, the executive vice president now owns 144,821 shares in the company, valued at approximately $2,178,107.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 12.42% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. EcoR1 Capital LLC boosted its position in Assembly Biosciences by 301.5% during the 4th quarter. EcoR1 Capital LLC now owns 2,388,268 shares of the biopharmaceutical company’s stock valued at $48,864,000 after purchasing an additional 1,793,368 shares during the period. Jennison Associates LLC boosted its position in Assembly Biosciences by 0.3% during the 4th quarter. Jennison Associates LLC now owns 2,346,510 shares of the biopharmaceutical company’s stock worth $48,010,000 after acquiring an additional 6,132 shares during the period. BlackRock Inc. boosted its position in Assembly Biosciences by 15.6% during the 1st quarter. BlackRock Inc. now owns 2,297,866 shares of the biopharmaceutical company’s stock worth $34,079,000 after acquiring an additional 310,648 shares during the period. Victory Capital Management Inc. boosted its position in Assembly Biosciences by 30,224.0% during the 4th quarter. Victory Capital Management Inc. now owns 1,325,460 shares of the biopharmaceutical company’s stock worth $27,119,000 after acquiring an additional 1,321,089 shares during the period. Finally, Franklin Resources Inc. acquired a new position in Assembly Biosciences during the 4th quarter worth $14,829,000. Institutional investors and hedge funds own 88.34% of the company’s stock.
ASMB stock traded up $0.65 during midday trading on Friday, hitting $23.81. 166,900 shares of the company’s stock were exchanged, compared to its average volume of 261,602. The company has a current ratio of 12.14, a quick ratio of 12.14 and a debt-to-equity ratio of 0.03. Assembly Biosciences has a 12-month low of $8.13 and a 12-month high of $25.07. The firm has a 50 day moving average price of $20.86 and a 200-day moving average price of $18.82. The stock has a market capitalization of $757.85 million, a price-to-earnings ratio of -6.94 and a beta of 1.26.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.